AP Photo/Juan Karita, File A healthcare worker prepares a shot of the Pfizer COVID-19 vaccine . The Centers for Disease Control and Prevention may have handed Republican leaders a political grenade with the pin pulled.
On June 1, the agency awarded Pfizer contracts worth roughly $1.24 billion for COVID-19 vaccines for the remainder of fiscal 2026 and fiscal 2027, including hundreds of millions for pediatric doses and additional funds for adults.
The award raises serious questions: What demand projections, dose assumptions, or safety rationale justified such a purchase? And why would the government commit more than a billion taxpayer dollars to a product many Americans have stopped using, and which some no longer trust?
As of spring 2026, uptake for the COVID-19 vaccine was quite low. Nine percent of children were getting it and 17 percent of adults. Only 3 percent of parents plan to have it given to their children.
For those “Make America Healthy Again” voters essential to President Trump’s 2024 coalition, the optics are hard to ignore: The government that promised health reform has committed massive public funds to Pfizer, even as trust in and use of their product collapses.
The contract also moved forward despite the unresolved legal status of the Advisory Committee on Immunization Practices. A court had stayed the members appointed by Secretary Robert Kennedy and their votes, and the administration failed to appeal for six weeks. The panel remains in limbo, meaning Washington committed more than $1 billion to Pfizer through a broken legitimizing process.
This is not a bureaucratic footnote for the millions who backed Trump in 2024 as part of his coalition: It is a gut punch.
An October 2025 MAHA Action survey by Trump pollster Tony Fabrizio found overwhelming voter concern over vaccine mandates and pharmaceutical influence. Seventy-three percent were concerned about childhood vaccine mandates, while 90 percent were concerned about Big Pharma’s corrupting influence over government. Only 18 percent viewed pharmaceutical companies favorably, whereas more than 68 percent supported government-funded research into vaccine complications, the end of blanket liability shields and the return of vaccination decisions to families.
Unfortunately, that poll was never released publicly, and was only later unearthed by the Daily Caller. Instead, the White House cited narrower polling that framed questions around established vaccine policies — for example, whether the administration should “remove established childhood vaccine recommendations for diseases like whooping cough, measles, hepatitis and others.” That change of language drove support down to 22 percent. It softened the issue and blurred opposition.
This was used to justify a pivot away from vaccine accountability, toward the safer terrain of food dyes and seed oils. The contrast suggests what MAHA voters already suspected: The conversation was being managed toward a more convenient conclusion.
MAHA voters are not naive; they saw what happened, and Pfizer’s billion-dollar COVID contract confirms their worst suspicions.
Kennedy’s endorsement of President Trump in 2024 marked a historic political realignment, bringing millions of health-freedom voters into the Republican coalition: parents of vaccine-injured children, families affected by chronic disease, physicians and scientists alienated by captured regulators, and citizens who had lost faith in both parties. These were not conventional party voters. They came for a specific promise: that America’s public health apparatus would finally be held accountable and citizens would regain control over their own medical decisions.
To many of them, that promise now appears broken. Many of the MAHA movement’s most trusted voices, physicians such as Harvey Risch, Ryan Cole, and Pierre Kory, remain outside HHS and other critical health agencies. COVID vaccines remain on the childhood immunization schedule, the promised reckoning hasn’t arrived, and Pfizer has received another massive government contract.
A recent KFF poll found that among MAHA-supporting voters, 56 percent say health care costs will heavily influence which party’s candidate they support in November. About four in ten say the same of vaccine policy. These are not insignificant voters; in competitive districts, they may represent the winning margin.
A narrow Republican House majority leaves little room for error. Many of the seats likely to decide control of Congress run through suburban and exurban districts where MAHA voters live: educated, economically anxious, skeptical of institutional medicine, and motivated by the health-freedom movement. Depressing their turnout, or pushing a fraction toward third-party alternatives, could shift the balance of power.
The CDC-Pfizer deal risks more than depressing MAHA enthusiasm: it validates the narrative that the Republican establishment has capitulated to Big Pharma, that reformers have been neutralized, and that the MAHA coalition was useful during the campaign but expendable in government. With the movement demoralized by stalled reform and personnel decisions that sidelined trusted voices.
The larger lesson isn’t partisan; it is structural. MAHA voters’ concerns about pharmaceutical influence, vaccine mandates, liability shields, medical freedom, and families’ right to make their health decisions are not fringe positions. These concerns cross party lines and are held by voters who are growing more organized, less deferential, and less willing to be managed by either political party.
The lesson of the last year is clear: Tying the future of health freedom to any one political party is a failed strategy. The Republican Party benefited from the MAHA coalition in 2024, but if its leaders govern as if that coalition is meaningless, they should not be surprised when those voters look elsewhere.
Donald J. Slaughter, Sr. is a publisher and media executive focused on public accountability, medical freedom, and institutional reform.
Add as preferred source on Google Tags Robert KennedyCopyright 2026 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Comments: Link copiedMore Opinions - Healthcare News
See All
Opinions - Healthcare Most of Congress backs this bill to support breast cancer patients. Why isn’t it law? by Fran Visco, opinion contributor 3 days ago Opinions - Healthcare / 3 days ago 
